Nomic Bio
-50%
est. 2Y upside i
Nomic is doing for proteins what Illumina has done for DNA
Rank
#1247
Sector
Biotechnology
Est. Liquidity
~4Y
Data Quality
Data: MediumNomic Bio presents a moderate upside opportunity for a job seeker, with an estimated 75.5% expected return over a two-year horizon.
Last updated: March 10, 2026
Nomic Bio's nELISA platform achieves widespread adoption across drug discovery and diagnostics, driven by its superior throughput and cost-effectiveness. New applications and strategic partnerships propel revenue to over $100M by 2028, justifying a $1.05B valuation at 65x revenue, significantly above the current estimated $300M.
Nomic Bio continues to grow steadily within its niche of protein profiling for biopharma and research, maintaining its competitive edge but facing ongoing incumbent pressures. Revenue reaches ~$50M by 2028, leading to an acquisition or later-stage funding round at a $525M valuation, a moderate increase from the current estimated $300M.
Dominant incumbents like Thermo Fisher Scientific introduce more competitive high-throughput immunoassay solutions, or Nomic Bio faces significant scaling challenges and regulatory hurdles for diagnostic expansion. Growth stalls, leading to a down round or acquisition at $120M, wiping out a substantial portion of common stock value given the $63M in liquidation preferences.
Preference Stack Risk
highInvestors hold $63M in liquidation preferences ahead of common shareholders at an estimated $300M valuation.
Dilution Risk
moderateAs a Series B company, Nomic Bio will likely undergo further equity funding rounds (Series C, D) before an exit, leading to additional dilution for common shareholders.
Secondary Liquidity
limitedEquityZen offers pre-IPO shares for accredited investors, suggesting some limited secondary market activity for existing shareholders.
Questions to Ask at the Interview
Strategic questions based on Nomic Bio's data — designed to show you've done your homework.
- 1
“Given Thermo Fisher Scientific's established presence in immunoassay solutions, how does Nomic Bio plan to sustain its competitive advantage and market share as it scales, particularly with the Omni 1000 platform and its low price point?”
- 2
“With ~$16M in revenue and a Series B funding round, what are the key milestones for Nomic Bio's revenue growth and platform expansion over the next 2-3 years, and what are the primary drivers for achieving those targets?”
- 3
“Considering the significant capital raised to date and the potential need for future funding rounds, how does Nomic Bio envision the path to a liquidity event for employees, and what is the company's philosophy on managing dilution for common shareholders?”
Community
Valuation Sentiment
Our model estimates -50% upside. What do you think?
Anonymous. Do not share material non-public information.
Community Discussion
Comments are reviewed before they appear publicly.
Loading comments...
Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.